Double Digit NASDAQ Stock Winners: ALF, CLSD, FUSN

10:19 am Wednesday, June 16th, 2021

Following are major stock gainers on Nasdaq in Tuesday ‘s trading session:

Alfi, Inc. (NASDAQ:ALF) was the active stock gainer on Tuesday . The stock soared 104% to close $6.97 after the company announced that it has entered into an agreement with All-Niter for the fulfillment, staging and shipment of the first 10,000 digital tablets to Uber and Lyft drivers nationwide.

The DOOH world is transitioning rapidly to impression-based accountability with major advertisers and national brands demanding more transparency and better accuracy in reporting metrics. Alfi is far ahead of this curve, having already built, tested, and now deploying these advanced platforms in the OOH world globally. It is incredibly exciting to see these paramount shifts towards ALFI’s intelligent platform.

Clearside Biomedical (NASDAQ:CLSD) was another notable winner as the stock went up 37.75% to end the session at $4.16 after the biopharma reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration. The results prompted an analyst to call the treatment “a game changer.”

Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study. The company said the improvements after receiving an injection of CLS-AX for wet AMD were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) surged 18.15% to $9.64. The company announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Virtual Annual Meeting. The presentations and posters highlight the potential of Fusion’s targeted alpha therapies (TATs) to enable delivery of alpha particle emitting isotopes (225Ac) to targeted tumor cells.

In both the oral session and the poster titled, “Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [225Ac]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors,” results from the first three patient cohorts (n=12) demonstrated a favorable safety profile for [225Ac]-FPI-1434.